657 related articles for article (PubMed ID: 27039800)
1. Secretion and Expression of Matrix Metalloproteinase-2 and 9 from Bone Marrow Mononuclear Cells in Myelodysplastic Syndrome and Acute Myeloid Leukemia.
Chaudhary AK; Chaudhary S; Ghosh K; Shanmukaiah C; Nadkarni AH
Asian Pac J Cancer Prev; 2016; 17(3):1519-29. PubMed ID: 27039800
[TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes.
Ries C; Loher F; Zang C; Ismair MG; Petrides PE
Clin Cancer Res; 1999 May; 5(5):1115-24. PubMed ID: 10353746
[TBL] [Abstract][Full Text] [Related]
3. Biological and clinical relevance of matrix metalloproteinases 2 and 9 in acute myeloid leukaemias and myelodysplastic syndromes.
Travaglino E; Benatti C; Malcovati L; Della Porta MG; Gallì A; Bonetti E; Rosti V; Cazzola M; Invernizzi R
Eur J Haematol; 2008 Mar; 80(3):216-26. PubMed ID: 18081721
[TBL] [Abstract][Full Text] [Related]
4. High Expression of Human Homologue of Murine Double Minute 4 and the Short Splicing Variant, HDM4-S, in Bone Marrow in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome.
Han X; Medeiros LJ; Zhang YH; You MJ; Andreeff M; Konopleva M; Bueso-Ramos CE
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S30-8. PubMed ID: 27155969
[TBL] [Abstract][Full Text] [Related]
5. Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival.
Corradi G; Baldazzi C; Očadlíková D; Marconi G; Parisi S; Testoni N; Finelli C; Cavo M; Curti A; Ciciarello M
Stem Cell Res Ther; 2018 Oct; 9(1):271. PubMed ID: 30359303
[TBL] [Abstract][Full Text] [Related]
6. Expression of matrix metalloproteinases (MMP-2 and -9) and tissue inhibitors of metalloproteinases (TIMP-1 and -2) in acute myelogenous leukaemia blasts: comparison with normal bone marrow cells.
Janowska-Wieczorek A; Marquez LA; Matsuzaki A; Hashmi HR; Larratt LM; Boshkov LM; Turner AR; Zhang MC; Edwards DR; Kossakowska AE
Br J Haematol; 1999 May; 105(2):402-11. PubMed ID: 10233411
[TBL] [Abstract][Full Text] [Related]
7. Cytokine expression in adherent layers from patients with myelodysplastic syndrome and acute myelogenous leukemia.
Wetzler M; Kurzrock R; Estrov Z; Estey E; Talpaz M
Leuk Res; 1995 Jan; 19(1):23-34. PubMed ID: 7837815
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic criteria for hypocellular acute leukemia: a clinical entity distinct from overt acute leukemia and myelodysplastic syndrome.
Nagai K; Kohno T; Chen YX; Tsushima H; Mori H; Nakamura H; Jinnai I; Matsuo T; Kuriyama K; Tomonaga M; Bennett JM
Leuk Res; 1996 Jul; 20(7):563-74. PubMed ID: 8795690
[TBL] [Abstract][Full Text] [Related]
9. DICER1 gene and miRNA dysregulation in mesenchymal stem cells of patients with myelodysplastic syndrome and acute myeloblastic leukemia.
Ozdogan H; Gur Dedeoglu B; Oztemur Islakoglu Y; Aydos A; Kose S; Atalay A; Yegin ZA; Avcu F; Uckan Cetinkaya D; Ilhan O
Leuk Res; 2017 Dec; 63():62-71. PubMed ID: 29102598
[TBL] [Abstract][Full Text] [Related]
10. Expression of TNF receptors and related signaling molecules in the bone marrow from patients with myelodysplastic syndromes.
Sawanobori M; Yamaguchi S; Hasegawa M; Inoue M; Suzuki K; Kamiyama R; Hirokawa K; Kitagawa M
Leuk Res; 2003 Jul; 27(7):583-91. PubMed ID: 12681357
[TBL] [Abstract][Full Text] [Related]
11. Expression of type 1 insulin-like growth factor receptor in marrow nucleated cells in malignant hematological disorders: correlation with apoptosis.
Qi H; Xiao L; Lingyun W; Ying T; Yi-Zhi L; Shao-Xu Y; Quan P
Ann Hematol; 2006 Feb; 85(2):95-101. PubMed ID: 16328478
[TBL] [Abstract][Full Text] [Related]
12. Apoptosis, bcl-2 expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic-syndrome-derived acute myelogenous leukemia and de novo acute myelogenous leukemia.
Kurotaki H; Tsushima Y; Nagai K; Yagihashi S
Acta Haematol; 2000; 102(3):115-23. PubMed ID: 10692673
[TBL] [Abstract][Full Text] [Related]
13. miR-378 inhibits cell growth and enhances apoptosis in human myelodysplastic syndromes.
Kuang X; Wei C; Zhang T; Yang Z; Chi J; Wang L
Int J Oncol; 2016 Nov; 49(5):1921-1930. PubMed ID: 27633496
[TBL] [Abstract][Full Text] [Related]
14. Genomic loss of EZH2 leads to epigenetic modifications and overexpression of the HOX gene clusters in myelodysplastic syndrome.
Xu F; Liu L; Chang CK; He Q; Wu LY; Zhang Z; Shi WH; Guo J; Zhu Y; Zhao YS; Gu SC; Fei CM; Li X
Oncotarget; 2016 Feb; 7(7):8119-30. PubMed ID: 26812882
[TBL] [Abstract][Full Text] [Related]
15. Expression of CDKN1C in the bone marrow of patients with myelodysplastic syndrome and secondary acute myeloid leukemia is associated with poor survival after conventional chemotherapy.
Radujkovic A; Dietrich S; Andrulis M; Benner A; Longerich T; Pellagatti A; Nanda K; Giese T; Germing U; Baldus S; Boultwood J; Ho AD; Dreger P; Luft T
Int J Cancer; 2016 Sep; 139(6):1402-13. PubMed ID: 27170453
[TBL] [Abstract][Full Text] [Related]
16. The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes.
Tamaki H; Ogawa H; Ohyashiki K; Ohyashiki JH; Iwama H; Inoue K; Soma T; Oka Y; Tatekawa T; Oji Y; Tsuboi A; Kim EH; Kawakami M; Fuchigami K; Tomonaga M; Toyama K; Aozasa K; Kishimoto T; Sugiyama H
Leukemia; 1999 Mar; 13(3):393-9. PubMed ID: 10086730
[TBL] [Abstract][Full Text] [Related]
17. Comparison of blast percentage calculated based on bone marrow all nucleated cells and non-erythroid cells in myelodysplastic syndromes with erythroid hyperplasia.
Mashima K; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Ochi SI; Nagayama T; Umino K; Minakata D; Nakano H; Yamasaki R; Morita K; Kawasaki Y; Sugimoto M; Ishihara Y; Ashizawa M; Yamamoto C; Fujiwara SI; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
Ann Hematol; 2019 May; 98(5):1127-1133. PubMed ID: 30474718
[TBL] [Abstract][Full Text] [Related]
18. [Expression of autophagy related gene Beclin1 in myelodysplastic syndrome patients and its significance].
Wan SY; Zhang R; Wang YY; Cen JN; Zhou J; Yang Y; Jiang F; Chen ZX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Aug; 21(4):936-9. PubMed ID: 23998589
[TBL] [Abstract][Full Text] [Related]
19. Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome.
Boehrer S; Adès L; Tajeddine N; Hofmann WK; Kriener S; Bug G; Ottmann OG; Ruthardt M; Galluzzi L; Fouassier C; Tailler M; Olaussen KA; Gardin C; Eclache V; de Botton S; Thepot S; Fenaux P; Kroemer G
Oncogene; 2009 Jun; 28(22):2205-18. PubMed ID: 19398952
[TBL] [Abstract][Full Text] [Related]
20. The New Clinicopathologic and Molecular Findings in Myeloid Neoplasms With inv(3)(q21q26)/t(3;3)(q21;q26.2).
Wang HY; Rashidi HH
Arch Pathol Lab Med; 2016 Dec; 140(12):1404-1410. PubMed ID: 27628325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
